Genscript Biotech Corporation Genscript Biotech Corporation

Genscript Biotech Corporation

1548

Rang în acțiuni #2099
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Preț acțiune
$4.37
Capitalizare de piață
$9.84B
Schimbare (1 zi)
2.30%
Schimbare (1 an)
109.57%
Țară
HK
Tranzacționează Genscript Biotech Corporation (1548)

Categorie

Healthcare
Venituri pentru Genscript Biotech Corporation (1548)
Venituri în Jun 2026 TTM: $844.00M
Conform celor mai recente rapoarte financiare ale Genscript Biotech Corporation, venitul actual al companiei (TTM) este $844.00M. În anul 2023, compania a avut un venit de $839.53M o creștere față de venitul din anul 2022, care a fost de $625.70M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Genscript Biotech Corporation din 2013 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
2026 (TTM) $844.00M 41.97%
2024 $594.49M -29.19%
2023 $839.53M 34.17%
2022 $625.70M 27.67%
2021 $490.10M 25.39%
2020 $390.85M 42.98%
2019 $273.35M 18.33%
2018 $231.02M 51.34%
2017 $152.65M 33.04%
2016 $114.74M 32.32%
2015 $86.71M 23.88%
2014 $69.99M 16.45%
2013 $60.10M 0.00%
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
$12.62B 1,395.77%
US
$2.23B 163.98%
US
$15.74B 1,765.44%
AU
$6.02B 613.42%
NL
- -
CH